Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional P53

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-13-0157
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Multiple Defects Sensitize P53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase Inhibition

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2019English

CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Chk1 Inhibition Activates P53 Through P38 MAPK in Tetraploid Cancer Cells

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2008English

Therapy Resistance in Head and Neck Cancer Stem Cells

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2018English

RNF138 Confers Cisplatin Resistance in Gastric Cancer Cells via Activating Chk1 Signaling Pathway

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2018English

The P53-Reactivating Small Molecule RITA Induces Senescence in Head and Neck Cancer Cells

PLoS ONE
Multidisciplinary
2014English

Inhibition of YAP Function Overcomes BRAF Inhibitor Resistance in Melanoma Cancer Stem Cells

Oncotarget
Oncology
2017English

Loss-Of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer

PLoS ONE
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy